Media Contact:

Becky Vonsiatsky
W2O Group
Phone: 1-413-478-2003
Email: bvonsiatsky@w2ogroup.com

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix’s proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.


Chimerix Announces Preliminary Data from Ongoing Phase 1 Dose Escalation Study of Intravenous Brincidofovir in Healthy Subjects

In January 2017, Chimerix announced preliminary data from its single ascending dose study of intravenous brincidofovir in healthy subjects.

Chimerix Appoints Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer

In January 2017, Chimerix announced the appointments of Randall Lanier, PhD as Chief Science Officer, and Roy W. Ware, PhD, MBA as Chief Manufacturing and Technology Officer.